ArticleJournal of thoracic disease2026
Initial single-center experience with robot-assisted single-port major pulmonary resection: a retrospective study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative outcomes of robotic single-port vNOTES versus robotic-Xi assisted single-incision transumbilical surgery for hysterectomy.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The da Vinci Single-Port (SP) system is a robotic platform designed to facilitate uniportal surgery. This study aimed to evaluate the feasibility and safety of the da Vinci SP system for major pulmonary resections. Methods: We retrospectively reviewed patients with non-small cell lung cancer who underwent lobectomy or segmentectomy using the da Vinci SP system between August 2023 and June 2025. All procedures were performed through a uniportal subcostal incision. The primary endpoint was procedural feasibility, defined as completion of the planned operation without conversion to an alternative surgical approach or the addition of any supplemental ports. Secondary endpoints included safety and perioperative outcomes. Results: Nine patients were included: 8 (88.9%) had clinical stage I disease, and 1 (11.1%) with clinical stage IIB received neoadjuvant chemoimmunotherapy. The median age was 55.0 (range, 40.0-70.0) years, and 6 patients (66.7%) were women. Lobectomy was performed in 7 patients (77.8%), and segmentectomy in 2 (22.2%). The median operative and console times were 198.0 (range, 141.0-248.0) min and 151.0 (range, 105.0-190.0) min, respectively. All procedures were completed without conversion, and complete resection was achieved in all cases. The median pathologic tumor size was 20.0 (range, 0.0-40.0) mm. A median of 8.0 lymph node (LN) stations and 22.0 LNs were harvested. No Clavien-Dindo grade ≥ III complications occurred. One patient (11.1%) developed chylothorax, which was managed conservatively. The median durations of chest tube drainage and hospital stay were 3 and 4 days, respectively. Conclusions: Robot-assisted SP major pulmonary resections via a uniportal subcostal approach appear feasible and safe, demonstrating acceptable short-term postoperative outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.